Prostate Cancer Treatment in Shanghai: 2026 International Patient Guide

Shanghai Urologic Oncology

Shanghai's urology departments perform high volumes of robotic prostatectomy and offer the full spectrum from active surveillance to advanced systemic therapy including novel androgen receptor inhibitors and radioligand therapy.

Top Hospitals

Renji Hospital, SJTU — One of China's highest-volume robotic prostatectomy centers.

Changhai Hospital (Navy Medical University) — Strong urologic oncology program with surgical and systemic therapy.

Fudan University Shanghai Cancer Center (FUSCC) — Comprehensive prostate cancer MDT.

Huashan Hospital, Fudan — Robotic surgery and PSMA-targeted imaging.

Treatment by Risk Group

Low risk: Active surveillance, radical prostatectomy (robotic da Vinci), or radiotherapy (SBRT/IMRT).

Intermediate/high risk: Robotic prostatectomy + extended pelvic lymph node dissection; or radiotherapy + long-term ADT.

Metastatic hormone-sensitive (mHSPC): ADT + docetaxel or AR inhibitor (abiraterone, enzalutamide, apalutamide, darolutamide).

mCRPC: AR inhibitors, taxane chemotherapy, PARP inhibitors (olaparib for HRR mutations), Lu-177 PSMA radioligand therapy at selected centers.

Advanced Imaging

PSMA PET-CT (Ga-68 PSMA or F-18 PSMA) is available at Shanghai's major nuclear medicine departments for accurate staging and detection of biochemical recurrence.

Cost Reference

Robotic prostatectomy: ¥80,000–130,000. AR inhibitor therapy: ¥15,000–35,000/month. Lu-177 PSMA: approximately ¥100,000–150,000 per cycle (availability limited to selected centers).